SCHEMBL6548449

SCHEMBL6548449

CC(=NOCCCOc1c(Cl)cc(OCC=C(Cl)Cl)cc1Cl)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.43
PPARA Q07869 4/20 0.43
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
HIF1A Q16665 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NFKB1 P19838 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
OPRK1 P41145 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36
SCN5A Q14524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549701 0.98 PPARA (0.46) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6548927 0.97 PPARA (0.45) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6549355 0.97 PPARA (0.45) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6549827 0.95 PPARG (0.40) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6549771 0.94 PPARA (0.45) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6547187 0.93 PPARA (0.47) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6548516 0.92 PPARA (0.46) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6549849 0.89 NPC1 (0.37) PPARGPPARALMNASMN1; SMN2SLC6A4
SCHEMBL6548288 0.89 PPARA (0.44) PPARGPPARALMNASMN1; SMN2CYP1A2
SCHEMBL6547987 0.87 PPARA (0.41) PPARGPPARALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 PPARG 2821/4885PPARA 2987/4885LMNA 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.